Surgiguard
Phase 3Small molecule
Surgiguard is one of 10 small molecule programs targeting Ovarian cyst. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Ovarian Cyst
#DrugCompanyPhaseTrials
1Neo-Synephrine
EExela Pharma Sciences, LLC.
Approved
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Naropin
FFresenius Kabi Oncology Ltd.
Approved
Norethisterone Acetate
MMansoura University
Approved
Depot Medroxyprogesterone Acetate
AbbViePhase 2
Combined Oral Contraceptive Pills
WWoman's Health University Hospital, Egypt
Phase 3
Gynorest
SSolvay Pharmaceuticals
Phase 1
Surgiguard
SSeoul National University Hospital
Phase 3
Progestin
WWashington University School of Medicine
Phase 3
Femara
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Surgiguard. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details